英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
luoder查看　luoder　在百度字典中的解释百度英翻中〔查看〕
luoder查看　luoder　在Google字典中的解释Google英翻中〔查看〕
luoder查看　luoder　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Libtayo: Uses, Side Effects, Warnings - Drugs. com
    Libtayo (cemiplimab-rwlc) is used to treat metastatic cutaneous squamous cell carcinoma, basal cell carcinoma, and non-small cell lung cancer Includes Libtayo side effects, interactions and indications
  • LIBTAYO® (cemiplimab-rwlc) in Advanced NSCLC, BCC, CSCC . . .
    LIBTAYO is a prescription medicine used to treat adults with a type of skin cancer called basal cell carcinoma (BCC) when your BCC cannot be removed by surgery (locally advanced BCC) or when it has spread (metastatic BCC) and have previously received treatment with a hedgehog pathway inhibitor (HHI), or cannot receive treatment with a HHI
  • LIBTAYO (cemiplimab-rwlc) Label - Food and Drug Administration
    LIBTAYO is a programmed death receptor-1 (PD-1) blocking antibody indicated for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiation (1)
  • Libtayo® (cemiplimab) Approved in the European . . . - BioSpace
    The safety profile of Libtayo as adjuvant treatment of patients with CSCC at high risk of recurrence after surgery and radiation is consistent with the known safety profile for Libtayo monotherapy in advanced cancers In the trial, grade ≥3 adverse events (AEs) occurred in 24% of patients receiving Libtayo and 14% receiving placebo
  • Cemiplimab-rwlc (Libtayo) Updates 2025: Uses in cancer, Side . . .
    This article is about Cemiplimab-rwlc (Libtayo), its uses, side effects, dosage, and what to expect during treatment
  • LIBTAYO® Full Prescribing Information | Regeneron
    LIBTAYO in combination with platinum-based chemotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) with no EGFR, ALK or ROS1 aberrations and is:
  • Cemiplimab (Libtayo®) - ChemoExperts
    Treatment Name: Cemiplimab (Libtayo®) Cemiplimab (Libtayo®) is an Immunotherapy Regimen for Lung Cancer, Non-Small Cell Lung Cancer (NSCLC) How does cemiplimab work? Cemiplimab is designed to block the signals that tumor cells use to suppress the immune system allowing the immune system to attack the lung cancer cells Goals of therapy:
  • LIBTAYO® (cemiplimab-rwlc) | Official HCP Website
    LIBTAYO® (cemiplimab-rwlc) is a prescription medicine indicated for the treatment of adult patients with advanced NSCLC, CSCC, BCC, and as an adjuvant treatment for high-risk CSCC See Important Safety full Prescribing Information
  • Treating Squamous Cell Carcinoma | Squamous Cell Cancer . . .
    Treating advanced squamous cell cancers Different types of treatments might be used for SCCs that have spread beyond the skin Lymph node dissection: Removing regional (nearby) lymph nodes might be recommended for some SCCs that are very large or have grown deeply into the skin, as well as if the lymph nodes feel enlarged and or hard
  • Cemiplimab-rwlc (Libtayo®) - OncoLink
    About Cemiplimab-rwlc (Libtayo®) The immune system works by creating antibodies, which are proteins that attach to antigens found on the surface of a cell The antibody “calls” the immune system to attack the cell it is attached to, resulting in the immune system killing the cell Monoclonal antibodies are created in a lab to attach to the antigens found on specific types of cancer cells





中文字典-英文字典  2005-2009